Drug: Isentress (raltegravir potassium)
Approval Date: October 12, 2007
Scoop: Isentress is the first agent in the class of antiretroviral agents known as integrase inhibitors. The drug is designed to slow the advancement of HIV-1 infection by blocking the HIV integrase enzyme that the virus needs in order to multiply. The drug is forecasted to reach $900 million in sales by 2012.
FDA approves Isentress. Report
FDA panel endorses Merck's new AIDS drug. Report